Fig. 1
From: Exosomal DNAJB11 promotes the development of pancreatic cancer by modulating the EGFR/MAPK pathway
Exosomal DNAJB11 is a novel diagnostic biomarker for pancreatic cancer. A TEM and NTA of exosomes from healthy people (N-exo), patients with benign pancreatic disease (BP-exo), and patients with malignant pancreatic cancer (MP-exo) are shown. B Protein levels of N-exo, BP-exo, and MP-exo. (n = 6 per group). C Western blot validation of exosomal markers (CD9 and CD63) and DNAJB11 of N-exo, BP-exo, and PC-exo (n = 6 per group). D No significant difference between the sizes of N-exo, BP-exo, and PC-exo (n = 6 per group). E Exosomal DNAJB11 level distribution in clinical plasma samples. F ROC curve analysis of exosomal DNAJB11 between MP-exo and BP-exo groups. G ROC curve analysis of exosomal DNAJB11 between MP-exo and N-exo groups. H ROC curve analysis of exosomal DNAJB11 between BP-exo and N-exo groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, one-way ANOVA. The values are shown as mean ± standard error of the mean (SEM)